
NeurAxis, Inc. (NASDAQ:NRXS – Free Report) – Equities research analysts at Craig Hallum reduced their FY2026 earnings per share (EPS) estimates for NeurAxis in a report issued on Tuesday, November 17th. Craig Hallum analyst C. Knickerbocker now forecasts that the company will post earnings of ($0.81) per share for the year, down from their prior forecast of ($0.76). Craig Hallum also issued estimates for NeurAxis’ Q4 2026 earnings at ($0.21) EPS and FY2027 earnings at ($0.56) EPS.
Separately, Zacks Research raised shares of NeurAxis to a “hold” rating in a report on Friday, October 2nd. One investment analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, NeurAxis presently has an average rating of “Moderate Buy” and an average price target of $13.00.
NeurAxis Price Performance
Shares of NASDAQ:NRXS opened at $4.22 on Thursday. The business’s 50 day moving average price is $6.76 and its 200-day moving average price is $6.71. NeurAxis has a 1 year low of $2.42 and a 1 year high of $9.33. The firm has a market capitalization of $44.96 million, a price-to-earnings ratio of -2.29 and a beta of 1.39.
Institutional Investors Weigh In On NeurAxis
Institutional investors have recently bought and sold shares of the company. Empowered Funds LLC purchased a new stake in shares of NeurAxis during the third quarter worth $123,000. Money Concepts Capital Corp raised its position in shares of NeurAxis by 3.4% in the third quarter. Money Concepts Capital Corp now owns 235,674 shares of the company’s stock valued at $1,737,000 after buying an additional 7,645 shares during the last quarter. AIGH Capital Management LLC raised its position in shares of NeurAxis by 3.9% in the third quarter. AIGH Capital Management LLC now owns 540,292 shares of the company’s stock valued at $3,982,000 after buying an additional 20,354 shares during the last quarter. T3 Companies LLC acquired a new stake in shares of NeurAxis in the third quarter valued at about $200,000. Finally, Panoramic Capital LLC purchased a new position in shares of NeurAxis in the second quarter worth about $841,000. 11.77% of the stock is currently owned by institutional investors and hedge funds.
About NeurAxis
NeurAxis, Inc. is a medical technology company focused on developing neuromodulation therapies for chronic and functional pain conditions. Its approach uses percutaneous electrical nerve field stimulation (PENFS), which delivers mild electrical impulses through nerves associated with the brain-gut pathway. The company’s lead product, IB-Stim, is a wearable, minimally invasive device cleared by the U.S. Food and Drug Administration for use as an adjunctive treatment for functional abdominal pain associated with irritable bowel syndrome in patients ages 11 to 18 who have not responded to conventional therapy.
Recommended Stories
- Five stocks we like better than NeurAxis
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for NeurAxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeurAxis and related companies with MarketBeat.com's FREE daily email newsletter.
